Inventor · disambiguated record
Chang-Yuil Kang
Also filed as: KANG CHANG-YUIL
11 granted patents·6 pending applications·450 citations·filing 1996–2023
91Inventor score
Files withKANG CHANG-YUIL4CELLID CO LTD3LG CHEMICAL LTD2SEOUL NAT UNIV IND FOUNDATION2KOREA FOOD RES INST1
Top patents by PatentIndex Score
17 records- 0197US8617546B2Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibodyKANG CHANG YUIL·Filed 2012·Granted Dec 31, 2013·163 cites·5 claims
- 0288US9518126B2Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigenKANG CHANG-YUIL·Filed 2007·Granted Dec 13, 2016·10 cites·7 claims
- 0388US8445268B2Her-2/neu DNA vaccine having anti-cancer activityLEE JOON YOUB·Filed 2010·Granted May 21, 2013·10 cites·16 claims
- 0488US5928893AMonoclonal antibody specific for human 4-1BB and cell line producing sameLG CHEMICAL LTD·Filed 1996·Granted Jul 27, 1999·164 cites·6 claims
- 0583US6747050B1Isoxazoline derivative and a process for the preparation thereofLG CHEM INVESTMENT LTD·Filed 2000·Granted Jun 8, 2004·23 cites·13 claims
- 0683US6458934B1Humanized antibody specific for human 4-1BBLG CHEMICAL LTD·Filed 1999·Granted Oct 1, 2002·73 cites·4 claims
- 0770US10016475B2Composition for preventing, improving, or treating immune diseases comprising natural extracts as active ingredientsKOREA FOOD RES INST·Filed 2013·Granted Jul 10, 2018·4 cites·3 claims
- 0870US2010086550A1Anticancer agent comprising anti-pd-1 antibody or anti-pd-l1 antibodySEOUL NAT UNIV IND FOUNDATION·Filed 2009·Application pending·0 cites
- 0968US8883746B2α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredientKANG CHANG-YUIL·Filed 2007·Granted Nov 11, 2014·3 cites·19 claims
- 1058US8003093B2B cell-based vaccine loaded with the ligand of natural killer T cell and antigenSEOUL NAT UNIV IND FOUNDATION·Filed 2006·Granted Aug 23, 2011·0 cites·12 claims
- 1157US2025170179A1Vaccine comprising natural killer cells loaded with ligands of natural killer t cells and cancer antigensCELLID CO LTD·Filed 2023·Application pending·0 cites
- 1249US12098384B2Adenoviral vector not including replication competent adenovirus, and use thereofCELLID CO LTD·Filed 2022·Granted Sep 24, 2024·0 cites·14 claims
- 1349US2006074038A1Her-2 neu dna vaccine having anti-cancer activityPANGENOMICS CO LTD·Filed 2003·Application pending·0 cites
- 1448US2008317769A1Vaccine Composition Comprising Alpha-Galactosylceramide as an Adjuvant For Intranasal AdministrationKANG CHANG-YUIL·Filed 2006·Application pending·0 cites
- 1541US2003096976A1Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodiesFiled 2002·Application pending·0 cites
- 1637US2023293670A1Novel coronavirus recombinant spike protein, polynucleotide encoding same, vector comprising polynucleotide, and vaccine for preventing or treating coronavirus infection, comprising vectorCELLID CO LTD·Filed 2021·Application pending·0 cites
- 1735US10443040B2Method for preparing antigen-specific cytotoxic T-cells by using activated B-cells and use thereofSEOUL NAT UNIV R&DB FOUNDATION·Filed 2017·Granted Oct 15, 2019·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Chang-Yuil Kang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →